CTMI Cti Molecular Imaging - Common Stock (MM)

CTI Molecular Imaging Announces Resignation of Member of Senior Management KNOXVILLE, Tenn., Aug. 31 /PRNewswire-FirstCall/ -- CTI Molecular Imaging, Inc. (NASDAQ:CTMI), a leading provider of positron emission tomography (PET) equipment, molecular biomarkers and services, today announced the resignation of Thomas J. Hook, who most recently has served as Senior Vice President of CTI Molecular Imaging and President of CTI Solutions. Mr. Hook has resigned from CTI in order to accept a position with another company. "On behalf of all of us at CTI Molecular Imaging, I want to thank Tom for his many contributions to our organization. Under Tom's leadership, we established a strong presence in the distribution of scanners, as well as experienced a rapid growth in our PETNET operations. Through his focus on improving our sales capabilities, Tom has grown our market share and profitability in these key areas. Tom is a talented manager and a fine individual, and we wish him the very best in his new pursuits," said Ronald Nutt, Ph.D., President and Chief Executive Officer of CTI Molecular Imaging. CTI has not announced any promotions or replacements for the position. Mr. Hook's resignation is effective September 1, 2004. About CTI Molecular Imaging: CTI Molecular Imaging, Inc. is a leading supplier of products and services for positron emission tomography (PET), a diagnostic imaging technology used in the detection and treatment of cancer, neurological disorders, and cardiac disease. Additional information is available at: http://www.ctimi.com/ . Certain matters discussed in this press release constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements, which may be identified by words such as "assume," "expect," "anticipate," "intend," "estimate" or similar expressions, include statements regarding the anticipated financial impact and operational improvements resulting from the new distribution arrangement with Siemens and any other statements that necessarily depend on future events. Forward-looking statements involve a number of risks and uncertainties and there can be no assurance that any forward-looking statements will prove to be accurate. Various factors could cause actual results to differ materially from those anticipated in the forward-looking statements. CTI undertakes no obligation to update or revise any forward-looking statements. Further information regarding risks, uncertainties and other factors that could adversely affect CTI or cause actual results to differ materially from those anticipated in forward-looking statements are included in CTI's Annual Report on Form 10-K for the fiscal year ended September 30, 2003 and Quarterly Report on Form 10-Q for the quarter ended June 30, 2004. DATASOURCE: CTI Molecular Imaging, Inc. CONTACT: Michael A. Lawless of CTI Molecular Imaging, Inc., +1-865-218-2000 Web site: http://www.ctimi.com/

Copyright